概述
-
货号
KDE43401
-
检测方法
Colorimetric -
样本类型
Plasma, Serum -
实验类型
Quantitative -
检测范围
0.31-5 μg/mL -
灵敏度
0.156 μg/ml -
精准度
CV<20%
-
回收率
80-120% -
运输
2-8 ℃ -
稳定性和存储
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. -
别名
BMS-986015, IPH2102, CAS: 1000676-41-4
-
背景
Lirilumab (IPH2102/BMS-986015/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PrECOG LLC.
图片
参考文献
评价
